In a report released on April 5, Edward Woo from Ascendiant maintained a Buy rating on NRX Pharmaceuticals (NRXP – Research Report), with a price target of $4.75. The company’s shares closed yesterday at $0.58.
According to TipRanks, Woo is an analyst with an average return of -1.7% and a 41.36% success rate. Woo covers the Healthcare sector, focusing on stocks such as BioSig Technologies, Vivos Therapeutics, and Biolase.
NRX Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $3.25.
See today’s best-performing stocks on TipRanks >>
NRXP market cap is currently $39.36M and has a P/E ratio of -0.95.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Big Rock Partners Acquisition Corp. is a blank check company, which was formed for the purpose of entering into a merger, stock exchange, asset acquisition, stock purchase, reorganization, recapitalization or other similar business combination with one or more businesses or entities. It focuses on identifying a prospective target business in the senior housing and care industry in the United States. The firm’s care segments are commonly divided into four categories: Independent Living; Assisted Living; Memory Care and Nursing Care. The company was founded on September 18, 2017 and is headquartered in Delray Beach, FL.
Read More on NRXP:
- NRx Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Business Update
- Nrx Pharmaceuticals, Inc. (NRXP) Q4 Earnings Cheat Sheet
- NRx Pharmaceuticals announces DSMB recommendation to continue NRX-101 enrollment
- NRx Pharmaceuticals issued patent by USPTO
- NRx Pharmaceuticals reports NRX-10 SPA granted in 2019 remains in effect
